Please assess the completion status of the following clinical trial:

Trial Title: Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month.~* Typically experiences moderate to severe migraine pain preceded by a mild pain phase.~* Differentiate between mild migraine pain and other headache types.~* Women of childbearing potential must be on adequate contraception.~Exclusion Criteria:~* Pregnant and/or nursing mother.~* History of cardiovascular disease.~* Uncontrolled hypertension.~* Basilar or Hemiplegic migraine.~* History of stroke or transient ischemic attacks (TIA).~* History of epilepsy or treated with anti-epileptics within past 5 years.~* Impaired hepatic or renal function.~* History of gastrointestinal bleeding or ulceration.~* Allergy or hypersensitivity to aspirin or any other NSAID.~* Allergy or hypersensitivity to triptans.~* Participated in an investigational drug trial in the previous 4 weeks.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- arm 1 (Type: EXPERIMENTAL): Treximet (sumatriptan/naproxen sodium)
- arm 2 (Type: PLACEBO_COMPARATOR): placebo to match

Based on this trial design, predict the completion outcome and termination type (if applicable).